{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:53:39Z","timestamp":1776210819762,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ajoc.2025.102272","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:41:04Z","timestamp":1738755664000},"page":"102272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Multimodal treatment with Neoadjuvant chemotherapy for eyelid and periocular sebaceous gland carcinoma: Long-term outcomes"],"prefix":"10.1016","volume":"38","author":[{"given":"Vijitha S.","family":"Vempuluru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshika","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Anand","family":"Reddy Palkonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-9961","authenticated-orcid":false,"given":"Swathi","family":"Kaliki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2025.102272_bib1","series-title":"Neoadjuvant Therapy","year":"2024"},{"issue":"Suppl 3","key":"10.1016\/j.ajoc.2025.102272_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/3.suppl_3.S11","article-title":"Chemotherapy of head and neck cancer","volume":"3","author":"Forastiere","year":"1992","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ajoc.2025.102272_bib3","first-page":"473","article-title":"Sebaceous gland carcinoma of the eyelid: complete response to sequential combination chemotherapy","volume":"46","author":"Paschal","year":"1985","journal-title":"N C Med J"},{"issue":"4","key":"10.1016\/j.ajoc.2025.102272_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.iop.0000169426.57497.24","article-title":"Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis","volume":"21","author":"Murthy","year":"2005","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"10.1016\/j.ajoc.2025.102272_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/IOP.0b013e3181c32515","article-title":"Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy","volume":"26","author":"Priyadarshini","year":"2010","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"10","key":"10.1016\/j.ajoc.2025.102272_bib6","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00417-013-2382-8","article-title":"Avoidance of exenteration in orbital sebaceous gland carcinoma with neoadjuvant chemotherapy","volume":"251","author":"Gogia","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2025.102272_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/IOP.0000000000000398","article-title":"Neoadjuvant systemic chemotherapy in the management of extensive eyelid sebaceous gland carcinoma: a study of 10 cases","volume":"32","author":"Kaliki","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.ajoc.2025.102272_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000515857","article-title":"Neoadjuvant systemic chemotherapy in sebaceous gland carcinoma of the eyelid: a retrospective study","volume":"7","author":"Verma","year":"2021","journal-title":"Ocul Oncol Pathol"},{"issue":"3","key":"10.1016\/j.ajoc.2025.102272_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000491549","article-title":"Malignant eyelid tumors in India: a study of 536 asian Indian patients","volume":"5","author":"Kaliki","year":"2019","journal-title":"Ocul Oncol Pathol"},{"issue":"2","key":"10.1016\/j.ajoc.2025.102272_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2004.12.008","article-title":"Sebaceous carcinoma of the ocular region: a review","volume":"50","author":"Shields","year":"2005","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajoc.2025.102272_bib11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cam4.444","article-title":"Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer","volume":"4","author":"Desai","year":"2015","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ajoc.2025.102272_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijom.2023.03.007","article-title":"The efficacy of neoadjuvant chemotherapy as compared to upfront surgery for the management of oral squamous cell carcinoma: a systematic review and meta-analysis","volume":"53","author":"Kende","year":"2024","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.ajoc.2025.102272_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10792-024-03256-w","article-title":"Neoadjuvant chemotherapy for advanced eyelid and periocular sebaceous gland carcinoma: a study of 25 cases","volume":"44","author":"Vempuluru","year":"2024","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajoc.2025.102272_bib14","series-title":"AJCC Cancer Staging Manual","first-page":"779","article-title":"Eyelid carcinoma","author":"Esmaeli","year":"2017"},{"key":"10.1016\/j.ajoc.2025.102272_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e18528","article-title":"Factors associated with default of treatment and follow-up among cancer patients","volume":"40","author":"Kumar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ajoc.2025.102272_bib16","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ajoc.2025.102272_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/ph15020255","article-title":"Gender and sex-related differences in normal tissue effects induced by platinum compounds","volume":"15","author":"Marcu","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ajoc.2025.102272_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000360806","article-title":"Long-term remission of an aggressive sebaceous carcinoma following chemotherapy","volume":"6","author":"Orcurto","year":"2014","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.ajoc.2025.102272_bib19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/eye.2015.79","article-title":"Sebaceous gland carcinoma of the eyelid: clinicopathological features and outcome in Asian Indians","volume":"29","author":"Kaliki","year":"2015","journal-title":"Eye."},{"issue":"4","key":"10.1016\/j.ajoc.2025.102272_bib20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41433-022-02025-2","article-title":"Sebaceous gland carcinoma: analysis based on the 8th edition of American Joint Cancer Committee classification","volume":"37","author":"Morawala","year":"2023","journal-title":"Eye (Lond)."},{"issue":"10","key":"10.1016\/j.ajoc.2025.102272_bib21","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1038\/s41433-020-01340-w","article-title":"Pagetoid tumour spread in periocular sebaceous gland carcinoma: a comparative analysis in 130 patients","volume":"35","author":"Kaliki","year":"2021","journal-title":"Eye (Lond)."},{"issue":"3","key":"10.1016\/j.ajoc.2025.102272_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-4632.2008.03496.x","article-title":"Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid","volume":"47","author":"Husain","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ajoc.2025.102272_bib23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.12659\/AJCR.912552","article-title":"A case report of recurrent metastatic sebaceous carcinoma which showed favorable response tt non-fluorouracil based chemotherapy","volume":"19","author":"Lee","year":"2018","journal-title":"Am J Case Rep"},{"issue":"6","key":"10.1016\/j.ajoc.2025.102272_bib24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expet Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.ajoc.2025.102272_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1188\/14.CJON.581-585","article-title":"5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice","volume":"18","author":"Latchman","year":"2014","journal-title":"Clin J Oncol Nurs"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993625000258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993625000258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:25:26Z","timestamp":1760145926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993625000258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"alternative-id":["S2451993625000258"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2025.102272","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal treatment with Neoadjuvant chemotherapy for eyelid and periocular sebaceous gland carcinoma: Long-term outcomes","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2025.102272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102272"}}